105 related articles for article (PubMed ID: 7577096)
1. Evaluation of amifostine for protection against cisplatin-induced serious hearing loss in children treated for average-risk or high-risk medulloblastoma.
Gurney JG; Bass JK; Onar-Thomas A; Huang J; Chintagumpala M; Bouffet E; Hassall T; Gururangan S; Heath JA; Kellie S; Cohn R; Fisher MJ; Panandiker AP; Merchant TE; Srinivasan A; Wetmore C; Qaddoumi I; Stewart CF; Armstrong GT; Broniscer A; Gajjar A
Neuro Oncol; 2014 Jun; 16(6):848-55. PubMed ID: 24414535
[TBL] [Abstract][Full Text] [Related]
2. Amifostine Prophylaxis in Irradiated Breast Reconstruction: A Study of Oncologic Safety In Vitro.
Luby AO; Subramanian C; Buchman LK; Lynn JV; Urlaub KM; Nelson NS; Donneys A; Cohen MS; Buchman SR
Ann Plast Surg; 2020 Oct; 85(4):424-429. PubMed ID: 31850964
[TBL] [Abstract][Full Text] [Related]
3. 3-Heptylidene-4,6-Dimethoxy-3
das Neves SC; de Araújo FH; Correa WA; Martins ACF; Coelho HRS; Vilela MLB; do Nascimento VA; Kassuya CAL; de Lima DP; Beatriz A; Oliveira RJ; Gomes RDS
Molecules; 2023 Jan; 28(3):. PubMed ID: 36770711
[TBL] [Abstract][Full Text] [Related]
4. Interventions for preventing neuropathy caused by cisplatin and related compounds.
Albers JW; Chaudhry V; Cavaletti G; Donehower RC
Cochrane Database Syst Rev; 2014 Mar; 2014(3):CD005228. PubMed ID: 24687190
[TBL] [Abstract][Full Text] [Related]
5. Interventions for preventing neuropathy caused by cisplatin and related compounds.
Albers JW; Chaudhry V; Cavaletti G; Donehower RC
Cochrane Database Syst Rev; 2011 Feb; (2):CD005228. PubMed ID: 21328275
[TBL] [Abstract][Full Text] [Related]
6. Use of amifostine in the treatment of recurrent solid tumours in children.
Sidi V; Arsos G; Papakonstantinou E; Hatzipantelis E; Fragandrea I; Gombakis N; Koliouskas E
Hippokratia; 2007 Jan; 11(1):25-9. PubMed ID: 19582173
[TBL] [Abstract][Full Text] [Related]
7. Toxicity patterns of cytotoxic drugs.
Chatelut E; Delord JP; Canal P
Invest New Drugs; 2003 May; 21(2):141-8. PubMed ID: 12889735
[TBL] [Abstract][Full Text] [Related]
8. The sulfhydryl containing compounds WR-2721 and glutathione as radio- and chemoprotective agents. A review, indications for use and prospects.
Hospers GA; Eisenhauer EA; de Vries EG
Br J Cancer; 1999 May; 80(5-6):629-38. PubMed ID: 10360638
[TBL] [Abstract][Full Text] [Related]
9. Pharmacologic approaches to protection against radiation-induced lethality and other damage.
Weiss JF
Environ Health Perspect; 1997 Dec; 105 Suppl 6(Suppl 6):1473-8. PubMed ID: 9467066
[TBL] [Abstract][Full Text] [Related]
10. Protection of normal tissues from the cytotoxic effects of chemotherapy and radiation by amifostine (WR-2721): preclinical aspects.
Peters GJ; van der Vijgh WJ
Eur J Cancer; 1995; 31A Suppl 1():S1-7. PubMed ID: 7577093
[TBL] [Abstract][Full Text] [Related]
11. Amifostine: an update on its clinical status as a cytoprotectant in patients with cancer receiving chemotherapy or radiotherapy and its potential therapeutic application in myelodysplastic syndrome.
Culy CR; Spencer CM
Drugs; 2001; 61(5):641-84. PubMed ID: 11368288
[TBL] [Abstract][Full Text] [Related]
12. Protection of normal tissue from the cytotoxic effects of chemotherapy and radiation by amifostine: clinical experiences.
Capizzi RL; Oster W
Eur J Cancer; 1995; 31A Suppl 1():S8-13. PubMed ID: 7577096
[TBL] [Abstract][Full Text] [Related]
13. The potential of amifostine: from cytoprotectant to therapeutic agent.
Santini V; Giles FJ
Haematologica; 1999 Nov; 84(11):1035-42. PubMed ID: 10553165
[TBL] [Abstract][Full Text] [Related]
14. Protection of normal tissues from the cytotoxic effects of chemotherapy by amifostine (Ethyol): clinical experiences.
Capizzi RL
Semin Oncol; 1994 Oct; 21(5 Suppl 11):8-15. PubMed ID: 7973776
[TBL] [Abstract][Full Text] [Related]
15. Amifostine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as a radioprotector and cytotoxic chemoprotector.
Spencer CM; Goa KL
Drugs; 1995 Dec; 50(6):1001-31. PubMed ID: 8612469
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
